fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Bupropion HCL

All products: Limited Use (codes 423)

Zyban · DIN 02238441 · 150 mg · extended release tablet

Limited Use, Reason for Use code 423 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 423 required
Write on scriptReason for Use code 423 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 423
Reason for Use code 423 For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling. Network Note: Limited to 12 weeks (168 tablets) of reimbursement per 365 days per patient. Coverage limit: LU Authorization Period: 12 Weeks.
No interchangeable product listed in the Ontario extract
Zyban · DIN 02238441 Manufacturer: Valeant Canada Ltd.; listing date 2011-08-04 Health Canada: Marketed since 2021-06-04 · brand ZYBAN · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zyban: Formulary list price $1.35 per unit (the source does not state the unit; exact figure $1.3541). What the ministry pays, not the patient.

Ministry pays: $1.3541 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238441)

Source record
DIN 02238441: Zyban Raw flags: sec12=Y, sec3=Y Item: 920000632; group id 901; item number 2161; lccId 00210; manufacturer id VAL Source form: SR Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3541; ministry $1.3541 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238441 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61860
Shortage status: resolved shortage (ended February 18, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238441
Shortage record checked October 6, 2026
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications ZYBAN (bupropion hydrochloride) is indicated as smoking cessation treatment in conjunction with behavioural modification; nicotine replacement therapy may be used together with ZYBAN. Prior to a decision to prescribe a non-nicotine treatment including ZYBAN, thorough consideration should be given to the treatment option of nicotine replacement therapy alone. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see Potential association with behavioural and emotional changes, including self-harm). 1.2 Geriatrics Geriatrics (≥65 years of age): No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but because geriatric patients are more likely to have decreased renal function, greater sensitivity of some older individuals to bupropion cannot be ruled out (see Renal Impairment and 4 Dosage and Administration). https://pdf.hres.ca/dpd_pm/00080547.PDF PM date: 2025-05-16 Source product: ZYBAN; DIN 02238441; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Free programs for Smoking cessation (Ontario): Ontario Drug Benefit (ODB) Plan coverage of Champix® and Zyban® — coverage of varenicline (Champix®) and bupropion (Zyban®); generic varenicline and bupropion are Limited Use (Reason for Use code 423 for varenicline: 'For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling', limited to 12 weeks, 168 tablets, per 365 days; code 315 for bupropion) — patients who are seniors (age 65+), in long term-care homes, or those on social assistance (welfare or because of disability) — not stated (toronto.ca, September 9, 2026 ↗) Implementing STOP (Smoking Treatment for Ontario Patients) — publicly funded Nicotine Replacement Therapy (NRT) for your patients — residents of Ontario — free (intrepidlab.ca, September 9, 2026 ↗) STOP on the Net — free nicotine replacement therapy (NRT) patches and gum/lozenges for 6 weeks of treatment mailed to you within 2 weeks of enrollment — 18 years of age or older and lives within Ontario — free (intrepidlab.ca, September 9, 2026 ↗) Smokers' Helpline — quit coach for free, confidential, one-to-one support — patients who want tobacco use cessation counseling/support — free (toronto.ca, September 9, 2026 ↗) Pharmacy Smoking Cessation Program — smoking cessation counseling from a pharmacist — eligible ODB recipients — not stated (toronto.ca, September 9, 2026 ↗) The Guidebook also includes information on the Pharmacy Smoking Cessation Program for Ontario Drug Benefit recipients who want to quit smoking as part of the Ontario Government’s support to quit smoking. (ontario.ca, Updated August 24, 2023 ↗)